HRMY in the 13F filings
Harmony Biosciences HLDGS In · CUSIP 413197104
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 18 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 5 listed it in both
- Shares listed
- 11,389,307
- combined, among listed positions
- Reported value
- $320m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 21 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,129,082.
Managers listing HRMY in Q1 2026
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 954,359 shares now+722,663
- Two Sigma Investments LPexisting position · 733,443 shares now+526,490
- Invesco Ltdexisting position · 628,247 shares now+177,442
- Citadel Advisors LLCexisting position · 585,623 shares now+165,213
- Man Group PLCexisting position · 461,898 shares now+155,155
Reductions
- Janus Henderson Group Ltdexisting position · 16,402 shares now-305,893
- MFS Investment Managementexisting position · 270,013 shares now-271,268
- Jane Street Group LLCexisting position · 9,993 shares now-211,574
- Arrowstreet Capital LPexisting position · 1,382,113 shares now-109,492
- AQR Capital Management LLCexisting position · 716,246 shares now-97,643
New positions and exits
New (3)
Exited (2)
- Walleye Capital LLCwas $5.3m
- Wellington Management Group LLPwas $700k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $3.9m | n.a. | n.a. |
| Q4 2021 | 1 | $66m | n.a. | n.a. |
| Q1 2022 | 2 | $87m | n.a. | n.a. |
| Q2 2022 | 3 | $92m | n.a. | n.a. |
| Q3 2022 | 3 | $93m | n.a. | n.a. |
| Q4 2022 | 5 | $110m | n.a. | n.a. |
| Q1 2023 | 3 | $16m | n.a. | n.a. |
| Q2 2023 | 5 | $35m | n.a. | n.a. |
| Q3 2023 | 5 | $28m | n.a. | n.a. |
| Q4 2023 | 4 | $23m | 3 | 1 |
| Q1 2024 | 2 | $15m | 0 | 2 |
| Q2 2024 | 1 | $2.6m | 0 | 0 |
| Q3 2024 | 2 | $3.4m | 1 | 1 |
| Q4 2024 | 3 | $35m | 2 | 2 |
| Q1 2025 | 3 | $36m | 1 | 2 |
| Q2 2025 | 1 | $38m | 1 | 0 |
| Q3 2025 | 4 | $7.5m | 3 | 0 |
| Q4 2025 | 5 | $111m | 17 | 13 |
| Q1 2026 | 5 | $41m | 21 | 9 |
| Q2 2026 | 3 | $54m | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
HRMY and LLY →HRMY and JNJ →HRMY and VRTX →Choose a stock to compare with HRMY →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own HRMY, latest filings →Back to the 13F Explorer →